Get started
Author

Larissa Wagnerberger

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30
PDF
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
2025 · Norbert Heinrich, Norbert Heinrich, et al. · The Lancet Infectious Diseases · 20
PDF
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
2025 · Lilian Tina Minja, Isabella van der Feltz, et al. · The Lancet Infectious Diseases · 18
PDF
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5
PDF
A Prospective, Randomised, Open Label Phase 2b Dose-Finding Trial of Delpazolid in Combination with Bedaquiline, Delamanid and Moxifloxacin for Pulmonary Tuberculosis: DECODE
2024 · Lilian Tina Minja, Isabella van der Feltz, et al. · SSRN Electronic Journal
Works count: 5
Citation count: 73
H-index: 4
I10-index: 3
Year
Topic
Type